Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn about a paper by Yi-Long Wu et al. published in Journal of Thoracic Oncology:

“CROWN 5-year update: Asian subset

Lorlatinib vs. Crizotinib in 1L ALK lung cancer.

PFS HR 0.22 (NR vs. 9.2m)
5-year PFS: 63% vs. 7%
iCRR: 69% vs. 6%

Consistent with overall study results. Strong PFS and intracranial efficacy remains key.”

“First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study”

Authors: Yi-Long Wu, Hye Ryun Kim, Ross Soo, Chew Hooi Wong, Tony Mok et al.

Aakash Desai: Lorlatinib vs. Crizotinib in 1L ALK+ lung cancer